Centrum pro zdravi s.r.o.

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Heart failure2 trials
• Obesity2 trials
• Stroke2 trials
• Coronary artery disease1 trial
• Familial hypercholesterolaemia1 trial
• Type 1 diabetes1 trial
• Type 2 diabetes1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Completed3 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• AstraZeneca2 trials
• Amgen1 trial
• Amgen Inc.1 trial
• Astrazeneca AB1 trial
• Shionogi Inc.1 trial

Running trials

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure1 recruiting
• Obesity1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo and its safety and tolerability in participants 18 to 75 years of age with dyslipidemia

  2023-506197-12-00· Phase 2· Astrazeneca AB· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

  NCT06017609· Phase 2· Shionogi Inc.· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source